Clinical trials · California
Pulmonary Fibrosis clinical trials in California
We’re tracking 22 recruiting pulmonary fibrosis studies with a site in California — including Early Phase 1, Phase 1, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT06162884Recruiting
Using one scan to predict early scarred lung disease
This study uses a single lung scan to find early signs of progressive scarring (fibrosis) in people with pulmonary fibrosis. It may help doctors predict which patients will get worse faster.
Los Angeles, CaliforniaAges 18 years+ - NCT06238622RecruitingPhase 3
Long-term nerandomilast for pulmonary fibrosis follow-up
This trial offers long-term treatment with nerandomilast for people with pulmonary fibrosis who already completed an earlier nerandomilast study. It aims to see how safe and effective the drug is over a longer period.
Los Angeles, CaliforniaAges 18 years+ - NCT04930289Enrolling by invitation
Lung transplant registry for better donor lung preservation
This study builds a worldwide database to track and improve how donor lungs are preserved before transplant. Your information may help doctors choose and manage donor lungs more effectively.
Stanford, CaliforniaAges Any age - NCT06968845RecruitingPhase 2
Study of LTI-03 for Idiopathic Pulmonary Fibrosis
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
Los Angeles, CaliforniaAges 40 years+ - NCT06951217RecruitingPhase 2
Long-term safety study of an inhaled drug for lung scarring
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
Los Angeles, CaliforniaAges 18 years+ - NCT07201922RecruitingPhase 3
Can a new pill help slow lung changes in people with family risk?
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
Los Angeles, CaliforniaAges 40 years+ - NCT05975983RecruitingPhase 2
Oral treatment test for idiopathic pulmonary fibrosis
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
Los Angeles, CaliforniaAges 40 years+ - NCT06567717RecruitingPhase 2
Zinc and vitamin B3 supplement for IPF
This trial tests whether adding zinc and nicotinamide riboside (a vitamin B3-like supplement) to standard IPF treatment can help improve lung function. It is for people with IPF who are already seeing a lung doctor and live in certain states.
Los Angeles, CaliforniaAges 50 years+ - NCT06967805RecruitingPhase 2
Study of MTX-463 for Idiopathic Pulmonary Fibrosis
This trial tests an experimental drug called MTX-463 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if targeting a protein called WISP1 can slow lung scarring and help you breathe better.
Los Angeles, CaliforniaAges 40 years+ - NCT07284602RecruitingPhase 3
Comparing a new drug to pirfenidone for lung scarring
This trial tests a new medicine, LYT-100 (deupirfenidone), against the standard drug pirfenidone for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the new drug works better or has fewer side effects.
Palm Spring, CaliforniaAges 40 years+ - NCT05571059RecruitingPhase 2
Ifetroban pills for idiopathic pulmonary fibrosis
This trial studies ifetroban, an oral medicine, in people with idiopathic pulmonary fibrosis (IPF) to see if it improves outcomes and is safe. It may be an option if your IPF is confirmed on lung scans and your lung function tests meet the trial thresholds.
La Mesa, CaliforniaAges 40 years+ - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
La Jolla, CaliforniaAges 40 years+ - NCT05943535RecruitingPhase 3
Breathing treprostinil to slow progressive lung scarring
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
Los Angeles, CaliforniaAges 18 years+ - NCT05548283RecruitingPhase 4
Standard IV antibiotic timing for cystic fibrosis lung flare-ups
This study standardizes how IV aminoglycoside antibiotics are given during a 14-day treatment for cystic fibrosis (CF) lung flare-ups. It may help make treatment more consistent and easier to manage for people who need IV antibiotics.
Orange, CaliforniaAges 6 years+ - NCT01915511Recruiting
Long-term registry for new or worsening lung scarring
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
Los Angeles, CaliforniaAges 21 years+ - NCT05365802RecruitingEarly Phase 1
PET scan to study lung scarring in people with ILD
This early-phase study uses a special PET scan to look at a substance linked to lung scarring (fibrosis) in people with ILD (interstitial lung disease). The goal is to see whether the scan can help measure lung disease activity and support future treatment decisions.
Los Angeles, CaliforniaAges 18 years+ - NCT05988463RecruitingPhase 1
Study of artesunate for people with idiopathic pulmonary fibrosis
This study tests artesunate, a medicine that may help treat idiopathic pulmonary fibrosis (IPF), a condition that causes lung scarring. It is for people who are already taking other IPF treatments and want to see if adding artesunate can improve their condition.
Stanford, CaliforniaAges 40 years+ - NCT07652658RecruitingPhase 2
Study of AZD8965 for people with IPF
This trial tests a new drug called AZD8965 for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the drug can help people with IPF either on current treatments or not on standard therapy.
Newport Beach, CaliforniaAges 40 years+ - NCT06603246RecruitingPhase 1
Study of inhaled GDC-6988 for mucus lung diseases
This study tests an inhaled medicine (GDC-6988) to see if it is safe and helps clear mucus from the lungs in people with mucus-related lung diseases like chronic bronchitis, COPD, or bronchiectasis. You may qualify if your lung function is fairly stable and you produce daily mucus.
Palo Alto, CaliforniaAges 18 years+ - NCT06654752Recruiting
Simpler treatment for lung flare-ups in kids with CF
This study tests a streamlined approach to managing sudden lung symptoms (pulmonary exacerbations) in children with cystic fibrosis. It aims to see if a simpler treatment plan works as well as standard care, which could mean less time in the hospital and fewer disruptions to daily life.
Los Angeles, CaliforniaAges 3–18 - NCT07312734Recruiting
Testing new ways to find lung germs in CF
This study tests a new method to detect bacteria in the lungs of people with cystic fibrosis (CF) by analyzing mucus samples. It aims to improve how we diagnose and treat lung infections.
La Jolla, CaliforniaAges 16 years+ - NCT06262282Enrolling by invitation
Phage therapy for stubborn NTM infection in cystic fibrosis
This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.
Los Angeles, CaliforniaAges 6 years+
Where these studies are running in California
Institutions with a site for the recruiting pulmonary fibrosis studies listed above.
- Stanford University · 5 studies
- University of California, Los Angeles (UCLA) · 5 studies
- University of California, Davis Medical Center · 4 studies
- University of Southern California · 4 studies
- Cedars-Sinai Medical Center · 3 studies
- Paradigm Clinical Research · 3 studies
- University of California San Diego Health · 3 studies
- University of California, San Francisco · 3 studies
What taking part in a pulmonary fibrosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Pulmonary Fibrosis trials in other states
Common questions
- Are there pulmonary fibrosis clinical trials in California?
- Yes. We're currently tracking 22 recruiting pulmonary fibrosis studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a pulmonary fibrosis study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a pulmonary fibrosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New pulmonary fibrosis studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.